The Infectious Disease Research Institute (IDRI), a Seattle-based not-for-profit organization, has partnered with a full-service, Research Triangle, NC-based contract research organization called FHI Clinical to support full-service research capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19.
TrialSite News recently introduced Celularity, a clinical-stage therapeutic company to launch a clinical trial to investigate the use of Celularity’s NK cell therapy, currently under study for the treatment of various hematologic cancers and solid tumors, as a potential treatment option against COVID-19.
Can Cell Therapy Help Address Crisis?
The hope is that the Celularity’s cell therapy (IMPACT™ Platform) can be a way of offering patients the immune cells that might make a difference in combating the deadly pathogen. Novel therapies may make a difference, reports Ted Fitzgerald, FHI Clinical president and CEO. Fitzgerald noted, “When an outbreak like coronavirus occurs, new therapies and vaccines are vital and require rapid start-up of clinical trials.”
FHI Clinical Outbreak Guide
FHI offers information on the importance of building research capacity in an outbreak setting, leveraging existing research capacity, and strengthening and localizing health systems—see their FHI Clinical Outbreak Response Guide.
Who is IDRI?
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of global importance. By integrating capabilities, we strive to enable an efficient pathway to bring scientific innovation from the lab to the people who need it most.
FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches, and proven solutions to manage complex clinical research in resource-limited settings around the world. Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines.